If you’re a migraine sufferer and take over-the-counter meds, GlaxoSmithKline’s recent announcement may apply to you. The company has temporarily stopped production of Excedrin Extra Strength and Excedrin Migraine products.
Why has GlaxoSmithKline halted production of the popular pills? Inconsistencies in how the manufacturer transferred and weighed ingredients were found in both products. While GlaxoSmithKline doesn’t believe the migraine medications pose a safety risk right now, the current halt in production is a precaution as the company resolves the inconsistency issues.
In an emailed statement to Red Tricycle, a representative from GSK said, “Patient safety and product quality are our utmost priorities at GSK. Through routine quality control and assurance measures, we discovered inconsistencies in how we transfer and weigh ingredients for Excedrin Extra Strength Caplets and Geltabs and Excedrin Migraine Caplets and Geltabs. Based on the available data, GSK believes that the product does not pose a safety risk to consumers. However, as a precautionary measure, GSK Consumer Healthcare has voluntarily implemented a temporary discontinuation of production and distribution.”
As a result of the product discontinuation stores have pulled both migraine medications from their shelves. If you’re not sure what to do about your migraines, the GSK statement continued, “This is a short term issue for which we expect production to begin again shortly. In the meantime, other Excedrin products are available along with other pain-relieving drugs, but dosages may differ. Consumers should consult their pharmacist for the most suitable alternative product.”
Consumers should also contact their physician or other medical professional before choosing a new migraine medication or treatment.
Featured photo: Excedrin/GlaxoSmithKline